|
|
|
|
National Institutes of Health 2009,Aug,05; (Grant Number: 5R01GM080672-03)
[...]The biotechnological impact of this system could be huge, considering that many high profile, clinically relevant proteins, such as antibodies (e.g. herceptin.), cytokines (e.g. EPOGEN), and anticoagulants (e.g. Tenecteplase') are glycoproteins. At a more basic level, the [...]
|
|
|
National Institutes of Health 2009,Apr,02; (Grant Number: 5R01HL068144-09)
[...] growth and maintenance of normal cardiac structure and function. Clinical cardiotoxicity of the erbB2 antibody-based compound trastuzumab can be interpreted as a demonstration that this system is required for cardiac response to injury, or [...]
|
|
|
National Institutes of Health 2008,Dec,17; (Grant Number: 5R01CA122804-02)
[...] cells and that decreasing erbB activity with PD168393 and/or 4D5, the anti-erbB2 antibody from which Herceptin was derived, will retard the proliferation and survival of these cells. We will partner human[...]
|
|
|
National Institutes of Health 2008,Jul,29; (Grant Number: 5R01GM080672-02)
[...]The biotechnological impact of this system could be huge, considering that many high profile, clinically relevant proteins, such as antibodies (e.g. herceptin.), cytokines (e.g. EPOGEN), and anticoagulants (e.g. Tenecteplase') are glycoproteins. At a more basic level, the [...]
|
|
|
National Institutes of Health 2008,Mar,28; (Grant Number: 5R01HL068144-08)
[...] growth and maintenance of normal cardiac structure and function. Clinical cardiotoxicity of the erbB2 antibody-based compound trastuzumab can be interpreted as a demonstration that this system is required for cardiac response to injury, or [...]
|
|
|
National Institutes of Health 2007,Dec,07; (Grant Number: 1R01CA122804-01A2)
[...] cells and that decreasing erbB activity with PD168393 and/or 4D5, the anti-erbB2 antibody from which Herceptin was derived, will retard the proliferation and survival of these cells. We will partner human[...]
|
|
|
National Institutes of Health 2007,Oct,01; (Grant Number: 1Z01BC010654-04)
[...]lymph node. Towards that end we have labeled the dendrimer nanoparticle with Fab Herceptin and will investigate other targeting ligands. We also hope to develop methods of evaluating lymphedema[...]
|
|
|
National Institutes of Health 2007,Sep,28; (Grant Number: 1R01GM080672-01A1)
[...]The biotechnological impact of this system could be huge, considering that many high profile, clinically relevant proteins, such as antibodies (e.g. herceptin.), cytokines (e.g. EPOGEN), and anticoagulants (e.g. Tenecteplase') are glycoproteins. At a more basic level, the [...]
|
|
|
National Institutes of Health 2007,Apr,02; (Grant Number: 5R21NS054167-02)
[...]This is consistent with similar findings using blocking mAbs against EGFR (Erbitux) and HER2/neu (Herceptin) as reported specifically for gliomas. The specific aims of this proposal are to test the hypotheses that: 1.[...]
|
|
|
National Institutes of Health 2007,Mar,15; (Grant Number: 5R01HL068144-07)
[...] growth and maintenance of normal cardiac structure and function. Clinical cardiotoxicity of the erbB2 antibody-based compound trastuzumab can be interpreted as a demonstration that this system is required for cardiac response to injury, or [...]
|
 1 2 3 
|
